<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456363</url>
  </required_header>
  <id_info>
    <org_study_id>CS09128</org_study_id>
    <nct_id>NCT02456363</nct_id>
  </id_info>
  <brief_title>Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis</brief_title>
  <official_title>Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis—A Registry Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of
      ankylosing spondylitis patient safety and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, single center, treatment, open, randomized, controlled clinical trial to
      assess Adalimumab(Humira) style with NSAIDs for the treatment of patients with ankylosing
      spondylitis, a total of 300 are expected to be included in the consent form signed by the
      subject, will be randomly assigned to treatment groups with a control group of 150 people.

      Subjects to be returned in the first week outpatient follow 0,8,20,44,68,92 accept routine
      physical examination (weight, blood pressure, etc.), AS Scale (BASDAI, BASFI, BAS-G),
      fingertip ground tests, lumbar range of motion, chest expansion test, lateral bending test,
      the occipital bone measurements, physician global assessment (Physician global assessment),
      patient pain scores (VAS), AS quality of Life scale (ASQOL), SF-36 quality of life scale,
      Complete joint assessment, ASAS20 response criteria, assessment of laboratory analysis
      inflammation index (HS-CRP, IgA, ESR), safety index checks (CBC, SGPT, Serum creatinine,
      HBV-DNA if HbsAg (+), HCV -RNA if HCVAB.

      Subjects need to return OPD week 0, accept Anti-HBs, Anti-HBc, HBsAg, Anti-HCV. Subjects
      required to return to the first outpatient follow 0,20,92 weeks, pulmonary function tests.

      Therefore, the subjects in the 92 weeks of the trial, a total need for blood six times, each
      time for blood about 10 cc. And to assess side effects and adverse events (Adverse Event,
      AE), serious adverse events (Serious Adverse Event, SAE)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mSASSS (Modified Stoke Ankylosing Spondylitis Spinal Score)</measure>
    <time_frame>weeks 92</time_frame>
    <description>weeks 92 of the spinal injury</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>NSAIDs(+) and sulfasalazine(+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAIDs(+) and sulfasalazine(-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAIDs(-) and sulfasalazine(+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAIDs(-) and sulfasalazine(-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TNF alpha</intervention_name>
    <description>Depending on patient need to use different TNF alpha</description>
    <arm_group_label>NSAIDs(+) and sulfasalazine(+)</arm_group_label>
    <arm_group_label>NSAIDs(+) and sulfasalazine(-)</arm_group_label>
    <arm_group_label>NSAIDs(-) and sulfasalazine(+)</arm_group_label>
    <arm_group_label>NSAIDs(-) and sulfasalazine(-)</arm_group_label>
    <other_name>Drug: Adalimumab (Humira)</other_name>
    <other_name>Drug: Etanercept (Enbrel)</other_name>
    <other_name>Drug: Golimumab (Simponi)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NSAIDs and sulfasalazine</intervention_name>
    <description>randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)</description>
    <arm_group_label>NSAIDs(+) and sulfasalazine(+)</arm_group_label>
    <arm_group_label>NSAIDs(+) and sulfasalazine(-)</arm_group_label>
    <arm_group_label>NSAIDs(-) and sulfasalazine(+)</arm_group_label>
    <other_name>Drug: Arcoxia</other_name>
    <other_name>Drug: Celebrex</other_name>
    <other_name>Drug: Tonec</other_name>
    <other_name>Drug: Mobic</other_name>
    <other_name>Drug: sulfasalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old

          -  HLA B27 positive

          -  X ray examination

          -  Clinical symptoms and physical examination, the following three conditions are subject
             to at least two:

             i.lower back pain and morning stiffness symptoms persist more than 3 months ii. lumbar
             activity is restricted iii. chest expansion is restricted

          -  Active disease for four weeks or more (continue two examination BASDAI&gt;6, ESR&gt; 28 mm/1
             hr and CRP&gt;1 mg/dl)

        Exclusion Criteria:

          -  pregnant or breast-feeding women

          -  patients with active infections

          -  highly infectious patients

          -  Cancer or precancerous condition of the patient

          -  multiple sclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei C- C, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Chung Wei, M.D., Ph.D.</last_name>
      <phone>24739595</phone>
      <phone_ext>34718</phone_ext>
      <email>wei3228@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>GCRC</investigator_full_name>
    <investigator_title>Chief, Department of Critical Care Medicine and Division of Pulmonary Medicine</investigator_title>
  </responsible_party>
  <keyword>Adalimumab</keyword>
  <keyword>NSAIDs</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

